AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03184506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pre-warming
Description: On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
Study NCT03184506 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no warming
Description: patients were covered only with two layers of cotton blanket
Study NCT01028612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thermal ablation with external beam radiation
Description: thermal ablation with external beam radiation
Study NCT04195347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM4620
Description: IV
Study NCT01096498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Emergency Pill (BAY86-5028/Opxion)
Description: Single dose of one 0.75 mg coated tablet
Study NCT01096498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel (Postday)
Description: Single dose of one 0.75 mg tablet
Study NCT03290183 — intervention group
Intervention type: DEVICE
Intervention: Confocal laser endomicroscopy
Description: Real-time microscopic imaging technique
Study NCT04250428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demand intervention
Description: Women in the demand intervention arm will receive a home visit by a study nurse who will highlight the importance of supplementation and prophyllaxis to women. During this session, women will also be informed regarding side effects and the ideal timing of supplementation (after meals).
Study NCT04250428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supply intervention
Description: In order to directly test the importance of access barriers, we will deliver supplements as well as malaria chemo- prophyllaxis directly to women through home visits by study nurses.
Study NCT00719940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: 1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
Study NCT00719940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Waiting group
Description: No intervention
Study NCT03927586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: We will be using commercialized cognitive-based training programs in order to facilitate several cognitive functions. We will be targeting attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance different types of cognitive functions. Cognitive program difficulty will be adjusted automatically and continuously based on each participant's level of performance.
Study NCT03927586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise training
Description: The physical exercise programs will involve balance or strength training or aerobic exercises. These may include (but not limited to) stepping, walking, dancing, ball kicking and throwing, and etc. The exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period. The exercise intensity will be progressed as the participants improve their performance throughout practice. To prevent exercise-induced injuries, vital signs and the Borg Perceived Exertion Scale will be monitored and recorded in each training session. If the training therapist observed that the exercise may be too intense for the participants, he/she will immediately reduce the training intensity.
Study NCT04054726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial pulsed current stimulation (tPCS)
Description: Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
Study NCT04054726 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial pulsed current stimulation (tPCS)
Description: Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
Study NCT02743065 — intervention group
Intervention type: DEVICE
Intervention: HepaSphere with 50-75mg Doxorubicin
Description: HepaSphere with 50-75mg Doxorubicin
Study NCT04616040 — intervention group
Intervention type: DRUG
Intervention: Camrelizumab
Description: The recommended formulation of Camrelizumab is 200 mg every time, or 3 mg/Kg according to body weight, intravenously infused.
Study NCT03832673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
Study NCT03832673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
Study NCT02783313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pathogen reduced plasma-stored platelet concentrates
Description: Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
Study NCT02783313 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-stored platelet concentrates
Description: Platelet concentrates stored in plasma
Study NCT00496587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
Study NCT00496587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.
Study NCT00496587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg By Vein On Days 1 and 15.
Study NCT00822328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yakult®300
Description: Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week.
Study NCT00822328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Yakult®300
Description: Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week.
Study NCT00822328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota
Description: Lactobacillus casei strain Shirota
Study NCT01937884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition
Study NCT01937884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral Nutrition
Study NCT00674895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Study NCT01415375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Screening Education
Description: tailored telephone education on prostate cancer testing
Study NCT01415375 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fruit and Vegetable Intake Education
Description: tailored telephone education about fruit and vegetable consumption
Study NCT02008006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM
Description: High Dose Chemotherapy (HDT) containing :~* Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~* Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~* Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0
Study NCT00495859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition
Description: food for special medical purpose (FSMP)
Study NCT00495859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food for special medical purposes (FSMP)
Description: an isocaloric isonitrogenous non-specific nutritional support
Study NCT00005796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: GCSF is given after chemo administration
Study NCT00005796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gene therapy
Description: stem cells are collected and given back to the patients after chemotherapy adminstration
Study NCT00005796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: chemotherapy is administered every 21 days
Study NCT00005796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: chemotherapy is administered every 21 days.
Study NCT00005796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: chemotherapy is administered every 21 days
Study NCT00005796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Description: stem cells are reinfused after chemotherapy administration
Study NCT02806830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optive
Description: Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
Study NCT03158610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral fluorouracil
Study NCT03158610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral fluorouracil
Study NCT01690299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablet orally BID
Study NCT01690299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept 50 mg evaluator/subject-blinded SC QW injection
Study NCT01690299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablets BID
Study NCT01690299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablets BID
Study NCT01690299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
Study NCT01690299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
Study NCT04956939 — intervention group
Intervention type: DRUG
Intervention: Low dose levodopa
Description: Low frequency is defined as ≤ 3 LD doses a day
Study NCT04956939 — intervention group
Intervention type: DRUG
Intervention: High dose levodopa
Description: High frequency dosage is defined as ≥ 5 LD doses per day
Study NCT01588405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR
Description: Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
Study NCT03706469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T2
Description: TAK-831 T2 Tablets.
Study NCT02542098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYD tablets
Description: Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
Study NCT03667664 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy
Description: * Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~* Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people.
Study NCT03107507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
Study NCT03107507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
Study NCT01241006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
Study NCT01241006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 60mg PO q day for 5 days
Study NCT01828866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
Study NCT01828866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Reinforcement Approach
Description: CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring
Study NCT01828866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach
Description: CRA is based on behavioural therapy principles:~1. Functional analysis~2. Communication skills~3. Problem-solving skills~4. Sobriety sampling~5. Social networking~6. Refusal of substances~7. Reinforcing activities~8. Relapse management~9. Medication monitoring
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Confusion Assessment Method
Description: This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Behavioral Inattention Test
Description: This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
Study NCT03706469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831 T3
Description: TAK-831 T3 Tablets.
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Florida Mental Status Examination
Description: This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Geriatric Depression Scale
Description: Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
Study NCT03349411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kessler Foundation Neglect Assessment Process
Description: This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
Study NCT02719041 — intervention group
Intervention type: OTHER
Intervention: Immunohistochemistry staining method
Study NCT03421405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform™
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study NCT01211444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HGNS Treatment
Description: The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
Study NCT03292523 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
Study NCT03666195 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Dioxide Nanoparticles
Description: incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
Study NCT01636622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
Study NCT01636622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
Study NCT01636622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
Study NCT03569215 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: All included patients will be exposed to questionnaires and psychiatric diagnostic tests
Study NCT02077725 — intervention group
Intervention type: OTHER
Intervention: interdisciplinary polypharmacy clinic visit
Study NCT01672593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy exploration and glue application
Description: A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.